Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperlipidemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Hyperlipidemia. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2006-006328-20 Sponsor Protocol Number: HEL-C01-A Start Date*: 2008-06-03
    Sponsor Name:HELP Pharmaceuticals S.A.
    Full Title: A multicentre, randomised, double-blind, controlled with placebo clinical trial with parallel groups, for the evaluation of the efficacy and safety of combined treatment with L-carnitine and simvas...
    Medical condition: This study will evaluate the safety and efficacy of combined treatment with L- Carnitine and Simvastatin in reducing the Lipoprotein (a) and triglyceride level of patients with mixed hyperlipidemia...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003807-19 Sponsor Protocol Number: 0653A-071 Start Date*: 2004-12-21
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia
    Medical condition: Mixed hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027762 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006557-28 Sponsor Protocol Number: FENOPRA-III-06-1 Start Date*: 2007-05-07
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibr...
    Medical condition: Type 2 diabetic patients, as defined by the WHO without CVD and with CVD (Cardiovascular disease), with combined hyperlipidemia.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003237-16 Sponsor Protocol Number: GFT505-207-1 Start Date*: 2007-08-31
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, place...
    Medical condition: Patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000037-19 Sponsor Protocol Number: 0524B-024 Start Date*: 2008-07-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin...
    Medical condition: Mixed Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) SE (Completed) GB (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2022-001135-85 Sponsor Protocol Number: AROAPOC3-2003 Start Date*: 2022-09-06
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) PL (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001994-24 Sponsor Protocol Number: atorvastatin Start Date*: 2004-11-09
    Sponsor Name:Karolinska Institute Danderyd Hospital
    Full Title: Effects of atorvastatin on plasma fibrin gel structure and skin microvascular reactivity in patients with type 1 diabetes and dyslipidemia
    Medical condition: Hyperlipidemia in patients with diabetes seems associated with a thrombogenic plasma fibrin gel structure and impaired microvascular function. We hypothesize that lipid lowering with a statin leads...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005851-14 Sponsor Protocol Number: C LF0242780-01 05 02 Start Date*: 2007-03-19
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with m...
    Medical condition: Study in patients with mixed dyslipidemia (type IIb) at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-022041-19 Sponsor Protocol Number: ST198-DNCC-10-001 Start Date*: 2011-01-31
    Sponsor Name:RostaQuo S.p.A.
    Full Title: Effects of L-carnitine administration in patients with elevated Lp(a)levels.
    Medical condition: Dislipidemic patients with Lp(a)>35 mg/dl; LDL-C<190 mg/dl, TG<500 mg/dl
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062060 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001669-41 Sponsor Protocol Number: 141205 Start Date*: 2007-05-08
    Sponsor Name:Thessaloniki's Aristoteleio University
    Full Title: PROJECT TITLE: EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION
    Medical condition: 50 patients with hypertension and newly diagnosed mild hypercholesterolemia.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062060
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000515-15 Sponsor Protocol Number: C LF0242780-01 05 04 Start Date*: 2007-01-30
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monoth...
    Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg pravastatin alone.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000519-21 Sponsor Protocol Number: C LF0242780-01 05 03 Start Date*: 2006-06-29
    Sponsor Name:FOURNIER LABORATORIES IRELAND Ltd
    Full Title: A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with atorvastatin monotherapy...
    Medical condition: Study in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 10 mg atorvastatin alone
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027763 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001972-19 Sponsor Protocol Number: Feno Atorva Start Date*: 2007-01-22
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Study of atorvastatin and fenofibrate mediated effects on the metabolism and hepatic excretion of biliary compounds in gallstone patients.
    Medical condition: Gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003827-37 Sponsor Protocol Number: 20110109 Start Date*: 2012-01-06
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects
    Medical condition: Hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10020667 Hyperlipidemia LLT
    Population Age: Adults, Elderly Gender:
    Trial protocol: CZ (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002184-24 Sponsor Protocol Number: PLAN-EC-HIPERL-02 Start Date*: 2005-03-01
    Sponsor Name:MADAUS, S.A.
    Full Title: Ensayo clínico multicéntrico, comparativo, doble ciego, paralelo de dos vías, de los efectos del tratamiento con cutículas de semillas de Plantago Ovata sobre el perfil lipídico de pacientes afecto...
    Medical condition: Pacientes diagnosticados de hipercolesterolemia, con un colesterol LDL superior o igual a 130 mg/dl e inferior o igual a 189 mg/dl. Con dos factores de riesgo cardiovascular.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10020661 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005565-18 Sponsor Protocol Number: P05019 Start Date*: 2007-04-02
    Sponsor Name:Research and Development Department, University Hospital of South Manchester NHS Foundation Trust
    Full Title: Efficacy and tolerability of Ezetimibe in cardiac transplant recipients taking Cyclosporin
    Medical condition: Hyperlipidaemia in patients folowing cardiac transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10062060 Hyperlipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022258-17 Sponsor Protocol Number: EC09/099 Start Date*: 2011-09-20
    Sponsor Name:Instituto Aragonés de Ciencias de la Salud
    Full Title: Efecto de niacina/laropiprant en la concentración de lipoproteína (A) en relación a las concentraciones basales y al tamaño de lipoproteína (A).
    Medical condition: Tratamiento de los pacientes con hiperlipemia, especialmente cuando ésta combina hipertrigliceridemia, hipercolesterolemia y HDL-c bajo.
    Disease: Version SOC Term Classification Code Term Level
    13 10020661 Hiperlipemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000824-20 Sponsor Protocol Number: 239/2007 Start Date*: 2008-06-15
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Effects of ezetimibe in association with statins on postprandial lipemia in type 2 diabetic patients
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027433 SOC
    9.1 10013317 HLGT
    9.1 10062060 PT
    9.1 10020661 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006069-39 Sponsor Protocol Number: LPS16141 Start Date*: 2022-06-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoho...
    Medical condition: Non-alcoholic fatty liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004871 10082249 Nonalcoholic fatty liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA